EUVIMEDEUVIMED entdecken
Kommentar

In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk

David S Pisetsky

Annals of Internal Medicine · 2023

DOI: 10.7326/j22-0107 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von David S Pisetsky. Beteiligte Einrichtung: University Medical Center, Durham, North Carolina, USA (D.S.P.). Hauptthemen laut MEDLINE: Giant Cell Arteritis, Polymyalgia Rheumatica. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisPolymyalgia RheumaticaHumansAntibodies, Monoclonal, HumanizedGlucocorticoidsRandomized Controlled Trials as Topic

Substanzen

Antibodies, Monoclonal, HumanizedGlucocorticoidstocilizumab

Autor:innen und Institutionen

  • University Medical Center, Durham, North Carolina, USA (D.S.P.).

Zitieren

APA

Pisetsky, D. S. (2023). In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk. Annals of Internal Medicine. https://doi.org/10.7326/j22-0107

Vancouver

Pisetsky DS. In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk. Annals of Internal Medicine. 2023. doi:10.7326/j22-0107

BibTeX
@article{Pisetsky2023,
  author = {Pisetsky, David S},
  title = {In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j22-0107}
}
Kostenlos starten →